Federated Investors Inc. PA raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 184,469 shares of the company’s stock after purchasing an additional 5,554 shares during the quarter. Federated Investors Inc. PA owned 0.45% of Medpace Holdings worth $5,350,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of the company. Spark Investment Management LLC bought a new stake in shares of Medpace Holdings during the 1st quarter valued at $1,620,000. Tudor Investment Corp ET AL raised its position in shares of Medpace Holdings by 16.4% during the 1st quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock valued at $205,000 after acquiring an additional 967 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Medpace Holdings during the 1st quarter valued at $516,000. Fisher Asset Management LLC raised its position in shares of Medpace Holdings by 193.2% during the 2nd quarter. Fisher Asset Management LLC now owns 104,289 shares of the company’s stock valued at $3,024,000 after acquiring an additional 68,725 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Medpace Holdings by 47.1% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 452,555 shares of the company’s stock valued at $13,509,000 after acquiring an additional 144,815 shares during the last quarter. Institutional investors own 15.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/09/17/federated-investors-inc-pa-boosts-stake-in-medpace-holdings-inc-medp.html.
Several analysts have commented on MEDP shares. Credit Suisse Group reiterated an “outperform” rating and set a $36.00 target price (up previously from $35.00) on shares of Medpace Holdings in a research report on Tuesday, June 6th. Zacks Investment Research raised shares of Medpace Holdings from a “sell” rating to a “hold” rating and set a $33.00 price target for the company in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $31.00 price target (up previously from $30.00) on shares of Medpace Holdings in a report on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $34.75.
In related news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total value of $60,540,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 25.80% of the company’s stock.
Medpace Holdings, Inc. (MEDP) traded up 0.65% during trading on Friday, hitting $31.01. 124,080 shares of the stock were exchanged. The firm has a market cap of $1.22 billion and a PE ratio of 54.60. Medpace Holdings, Inc. has a 52 week low of $21.76 and a 52 week high of $38.94. The firm’s 50-day moving average is $31.45 and its 200 day moving average is $28.94.
Medpace Holdings (NASDAQ:MEDP) last released its earnings results on Monday, July 31st. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.08. Medpace Holdings had a net margin of 5.37% and a return on equity of 9.32%. The company had revenue of $94.60 million for the quarter, compared to analysts’ expectations of $92.71 million. During the same quarter last year, the business earned $0.45 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Analysts expect that Medpace Holdings, Inc. will post $1.43 earnings per share for the current fiscal year.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.